Mutational analysis of the P16-binding domain of cyclin-dependent kinase 4 in tumors in the head region of the pancreas

Heleen M. Ceha, Marjon J. Clement, Mirjam M. Polak, G. Johan A Offerhaus, Robbert J C Slebos

Research output: Contribution to journalArticlepeer-review

Abstract

Alterations in genes involved in cell cycle regulation are common in many tumor types. In pancreatic adenocarcinomas, inactivating mutations in the CDKN2 gene, encoding the cyclin-dependent kinase inhibitor p16, are frequently observed. CDKN2 mutations have also been identified in the germline of 50% of patients with hereditary melanoma. Interestingly, such patients also have an increased risk for pancreatic cancers. In melanoma- prone kindreds with CDKN2 wild-type status, a mutation in one of the targets of p16, cyclin-dependent kinase 4 (CDK4) was reported, which abolishes p16 inhibition. To test the possible involvement of CDK4 mutations in pancreatic carcinoma, we analyzed sequence alterations in the p16-binding domain of CDK4 in DNA isolated from 32 tumors in the head region of the pancreas. Alterations in the CDK4 region between codon 1 and codon 56 were not observed in any of the tumors. Our results do not support disruption of the p16 pathway through CDK4 mutation as an oncogenic mechanism in pancreatic head tumorigenesis.

Original languageEnglish (US)
Pages (from-to)85-88
Number of pages4
JournalPancreas
Volume17
Issue number1
StatePublished - Jul 1998
Externally publishedYes

Keywords

  • CDK4
  • Cyclin-dependent kinase 4
  • K-ras oncogene
  • P16 tumor suppressor gene
  • Pancreatic neoplasms

ASJC Scopus subject areas

  • Gastroenterology
  • Endocrinology

Fingerprint Dive into the research topics of 'Mutational analysis of the P16-binding domain of cyclin-dependent kinase 4 in tumors in the head region of the pancreas'. Together they form a unique fingerprint.

Cite this